RE:RE:Stonegate Initiates Coverage: $3.54-$9.34I like it!
"Our analysis results in a range of $3.54 to $9.34 per share value, offering considerable upside to the current trading price of $1.64. However, any additional alterations to the path towards commercialization over the next few years could notably impact our estimates. Also, we have not factored in any of the orphan indications recently disclosed by management, nor have we incorporated any new licensing deals for RVX-208. For the time being, we have utilized cash on hand plus equity as the resources to fund operations and the development pipeline going forward. Overall, we believe that our analysis offers a very conservative approach to the valuation potential for RVX-208; should this lead compound exceed our assumptions on any of the variables (penetration, pricing, margins, etc.), it is likely to garner a much higher multiple than the range produced by our model."